In this webinar, we will walk you through the tools and techniques to help contract research organizations and pharma R&D scientists incorporate automated purification technologies for hybridoma clonal selection, which will feed into novel
antibody discovery at a fraction of the time, cost, and effort of traditional micro-extraction approaches. Patented dispersive solid-phase extraction (dSPE) technology combined with the Hamilton robotics platform enables researchers to complete
tasks that traditionally require significant ‘hands-on and sneaker time’ into walk-away micro-elution methods. From titer estimation to quantitative binding, we will show you how automated micro-purification with dSPE will allow
scientists to focus more time on discovery and spend less time handling samples or programming automated platforms. Join Kemp Proteins scientists Carter Mitchell, Chief Technology Officer, and Joe Corvera, Director of Hybridoma Development,
as they talk about incorporating these tools into their workflow to prevent bottlenecks and increasing success.
At the end of this webinar, participants will:
- Recognize potential bottlenecks in identifying micro-elution techniques to speed protein and antibody discovery through automation
- Identify the advantages of utilizing high-throughput design of experiment tools to reduce costs
- Gain an understanding of the dispersive solid-phase extraction technology
- Design harmonized workflows that benefit your pharma clients
Carter Mitchell, PhD
Chief Technology Officer
Carter Mitchell is a protein chemist and structural biologist with 20 years of direct experience isolating and characterizing difficult proteins from various recombinant and natural sources. He earned a PhD in Structural Biology where he enzymatically
characterized and solved the structures of multidomain proteins involved in the biosynthesis of metabolites. During his first postdoctoral fellowship, he developed and led a drug discovery pipeline with a team of scientists that isolated and
characterized bioactive small-molecules and peptides from mammalian microbiomes as well as solved the structure of a unique peptide with novel secondary structural elements. At the National Cancer Institute, Carter focused on the isolation
of bioactive proteins from marine aqueous extracts, which required creative purification strategies and earned the Director’s Innovation Award. Prior to joining Kemp Proteins, he was the Chief Technology Officer and Director of Structural
Biology at a Biotech start-up where he built, developed, and implemented a protein expression and isolation laboratory and managed the protein production and purification team.
Joe Corvera, MS
Director of Hybridoma Development
Joe Corvera has more than 20 years of experience leading teams involved in protein and antibody development and production. He provides strong technical background and product management skills in the development, implementation, and successful
completion of client projects. Prior to his current role, Joe was responsible for project management of monoclonal and polyclonal antibody development for major pharmaceutical, biotechnology, and diagnostic clients at Precision Antibody. Before
his focus on antibody development, he was involved in immunology research at the University of Maryland School of Pharmacy and clinical diagnostics at The Johns Hopkins University, where he earned his Master’s degree.
Dr. Ana Gupte
Strategy, Finance and Innovation Leader and Advisor
AG Health Advisors
Dr. Ana Gupte is a Strategy, Finance and Innovation Leader and Advisor with over two decades of experience in the field of Healthcare Services & Digital Health.
Dr. Gupte is well recognized for her healthcare equity analyst coverage over two decades on Wall Street bookended by senior Corporate Strategy, Finance & Management Consulting roles. Most recently, Dr. Gupte served as SVP, Chief Strategy &
Innovation Officer at Florida Blue Cross Blue Shield & its parent GuideWell. Prior to the Street, she served as Managing Director Corporate Strategic Planning at Aetna, Inc, and also headed up the WorldWide Drug Development Strategy Department
at Pfizer. She started her career in healthcare as a Management Consultant at McKinsey & Company.
Dr. Gupte's thought leadership over 12 years of equity coverage in the firms of Sanford C. Bernstein, and Leerink Partners garnered multiple awards including Top 3 rankings by All America Institutional Investor and the FT StarMine Top Stock picker
award. She is a frequent contributor on CNBC, Bloomberg TV, and widely quoted in print media including the NY Times, WSJ, and Forbes.
She has a B.S in Chemical Engineering from Bombay University, an M.S. and Ph.D in Bioengineering from the Pennsylvania State University and has graduated from the two year Executive Management program in Business Administration from the Wharton
School of Business.
Cost: No Cost!